Spots Global Cancer Trial Database for CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Official Title: Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas

Study ID: NCT00185965

Conditions

Non-Hodgkin Lymphoma

Mycosis Fungoides

Interventions

CPG 7909

Study Description

Brief Summary: Brief summary TBD

Detailed Description: This is a single institution phase 1-2 trial to evaluate the safety, feasibility and efficacy of CpG injections (4 intratumoral injections followed by 6 peri-tumoral injections) combined with local irradiation in patients with recurrent low-grade lymphomas. Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy each day). CpG injections will be administered into the same tumor site within the 24 hours before and the 24 hours after the radiation, and on days 8 and 15. Weekly doses of CpG will be then administered subcutaneously in the region of previous injections for 6 additional doses.